Insmed (INSM) Announces EC Grants Marketing Authorization for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Tr

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Insmed (INSM) Announces EC Grants Marketing Authorization for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Tr

Insmed (INSM) Misses Q3 EPS by 2c, Revenues Miss

October 29, 2020 7:55 AM EDT

Insmed (NASDAQ: INSM) reported Q3 EPS of ($0.63), $0.02 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $43.6 million versus the consensus estimate of $46.07 million.

Third Quarter 2020 Financial Results

Total revenue for the third quarter ended September 30, 2020, was $43.6 million, comprising U.S. net sales of $42.0 million and ex-U.S. net sales of $1.6 million. This compares to total revenue of $38.9 million for the third quarter of 2019.Cost of product... More